The Women’s Health Initiative (WHI) is a long-term national health study funded by the National Heart, Lung, and Blood Institute, or NHLBI. The original WHI study began in the early 1990s and concluded in 2005. Since 2005, the WHI has continued as Extension Studies, which are annual collections of health updates and outcomes in active participants. The second Extension Study enrolled 93,500 women in 2010 and follow-up of these women continues through another extension that will conclude in 2020. NHLBI intends to fund the next Extension Study for the follow-up of WHI participants through 2027.
As with the original WHI study, the main areas of research are cardiovascular disease, cancers, and osteoporotic fractures. While WHI continues to focus on strategies to prevent the major causes of death, disability, and frailty in older women, the breadth and richness of the WHI data allow for the exploration and investigation of many more research questions on women’s health and aging.
To learn more about the original WHI study that began in the early 1990’s, including specific details about the three clinical trials and the observational study, visit the WHI program page on the NHLBI website.
On April 19th, 1991, Dr. Bernadine Healy, the first female director of the National
Institutes of Health,
announced plans for the WHI study.
The Fred Hutchinson Cancer Research Center in Seattle, WA was awarded the role of the WHI’s
Coordinating Center (CCC).
The CCC was responsible for maintaining consistency between the 40 clinical centers and
managing, and analyzing WHI data.
The first 16 vanguard clinical centers in the country were named and began recruitment.
24 additional clinical centers are named, bringing the total to 40, with recruiting sites in 23 states.
161,808 postmenopausal women enrolled in the WHI. Over 68,000 women were randomized to 1, 2 ,
clinical trials: the Hormone
Therapy (HT) Trial, the Diet Modification (DM) Trial, and the Calcium and Vitamin D (CaD)
in the Observation Study (OS).
The estrogen-plus-progestin arm of the HT trial was stopped. Early results showed women who
combination hormone therapy
had increased risk of coronary heart disease, stroke, pulmonary embolism, and breast cancer.
published in the Journal
of the American Medical Association (JAMA).
Early results of the estrogen-only arm of the HT trial showed increased risk of stroke and no
disease. The trial was halted after an average of 6.8 years of follow-up. Findings were
published in JAMA.
The DM Trial tested whether a low-fat diet reduced risk of breast and colorectal cancers,
and stroke in postmenopausal women.
Results showed no risk reduction of these diseases. The CaD Trial tested whether taking
Vitamin D reduced the risk of fractures and breast
and colorectal cancers. Results showed a modest increase in hip bone density, but no risk
breast and colorectal cancers.
All participants in the original WHI study were invited to enroll in the first extension
women enrolled and
health updates and outcomes were collected annually from 2005-2010.
Health updates and outcomes were collected annually from 2010 to 2015 for the over 93,500
enrolled in the second WHI extension
From 2012 to 2013, over 7,800 women in the 2nd WHI Extension Study participated in the Long
They provided a blood sample,
body measures, and performed physical function tests at an in-home visit.
An economic and health analysis of the effects of the WHI hormone therapy results indicated
cases, 4.3 million fewer combination HT users, 126,000 fewer breast cancer cases, and a
savings in medical expenses in the decade following the release of the trial results.
The WHI encourages researchers to ask novel questions and develop new studies using WHI’s
repository and biorepository. Investigators
have been proposing these ancillary studies since the beginning of the original WHI study.
In 2014, 500
ancillary studies had been approved.
The Association for Clinical and Translational Science awarded the WHI study the Team Science
the collaborative nature of
the investigators involved and the volume of high-quality scientific discoveries.
Additional funding allowed the Second Extension Study to continue until 2020. Health and
medical outcomes continue
to be collected annually from
the women who enrolled.
The American Association for Cancer Research awarded the WHI study the Team Science Award,
that the WHI community
of investigators are a collaborative group producing strong science.
The average age of women still active in WHI is 83 years and ranges from 71 to 103 years.
An organizational chart provides further information detailing the roles of individual WHI Steering Committee members. Please continue reading the next section to learn more about former PIs and key contributors to the Women’s Health Initiative over the past three decades.
The WHI study consisted of 40 Clinical Centers, several with additional satellite locations, during the recruitment and active intervention phase of WHI (1993-2005). During the WHI Extension Studies, the Clinical Centers, shown in the interactive map below, were consolidated into 10 Regional Centers in 2010. The WHI Clinical Coordinating Center (CCC) is located at the Fred Hutchinson Cancer Research Center, in Seattle, WA. The tables below show the investigator names and locations of the original Clinical Centers and the current Regional Centers. Visit the Contacts page for CCC and Regional Center contact information.
These WHI Investigators have a history of major contribution to WHI 5 or more years ago as Past Principal Investigator or Co-Investigator at the CCC, a Regional Center, or an original WHI site or while employed at the NIH. Past WHI chairs of a WHI standing committee also may qualify as Legacy Investigators.
The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services.
© 2021 Women’s Health Initiative. All rights reserved